The plasma potassium level is normally maintained within narrow limits and kidney is primarily in charge of maintaining total body potassium content. Patients with CKD are more prone to develop imbalances of potassium homeostasis, such as hyperkalemia, which is defined as a serum or plasma potassium level usually greater than 5.0 mEq/L to 5.5 mEq/L. Hyperkalemia is not common in the general population, affecting less than 5% of the worldwide population, however its prevalence in hospitalized patients is reaching up to 10%. The need for hyperkalemia treatment comes from the very severe consequences of the potassium concentration imbalances, such as cardiac dysrhythmia, peripheral neuropathy and an increased risk of all-cause mortality and hospitalization. The new potassium binder called Sodium Zirconium Cyclosilicate is a revolutionary step for the treatment and prevention of hyperkalemia in high-risk patients, such as those in therapy with RAASi. In healthy people, the colon normally accounts for a small portion, about 5% to 10%, of total K+ excretion, while in patients with kidney disease, colon affects 50% of potassium excretion, thus making it a potential target for therapeutic treatment of increased concentration of potassium. This is a big advancement since the development of hyperkalemia is associated with reduction or cessation of RAAS inhibitors, which are both cardio- and renoprotective, while the new potassium binding agent can both allow the maintenance of the optimal RAASi dose but also might allow for less dietary restrictions and therefore an improvement in the nutrition status, giving an advantage especially to patients on hemodialysis. Given the scarce clinical studies performed on Sodium Zirconium Cyclosilicate in dialysis patients, as well as the need to provide more information about its efficacy and safety profile, there is a call for our clinical study. In this study we focused on the efficacy and safety profile of Sodium Zirconium Cyclosilicate after 2 weeks and 1 month from the initiation of the therapy both in non – dialysed and dialysed patients.
The plasma potassium level is normally maintained within narrow limits and kidney is primarily in charge of maintaining total body potassium content. Patients with CKD are more prone to develop imbalances of potassium homeostasis, such as hyperkalemia, which is defined as a serum or plasma potassium level usually greater than 5.0 mEq/L to 5.5 mEq/L. Hyperkalemia is not common in the general population, affecting less than 5% of the worldwide population, however its prevalence in hospitalized patients is reaching up to 10%. The need for hyperkalemia treatment comes from the very severe consequences of the potassium concentration imbalances, such as cardiac dysrhythmia, peripheral neuropathy and an increased risk of all-cause mortality and hospitalization. The new potassium binder called Sodium Zirconium Cyclosilicate is a revolutionary step for the treatment and prevention of hyperkalemia in high-risk patients, such as those in therapy with RAASi. In healthy people, the colon normally accounts for a small portion, about 5% to 10%, of total K+ excretion, while in patients with kidney disease, colon affects 50% of potassium excretion, thus making it a potential target for therapeutic treatment of increased concentration of potassium. This is a big advancement since the development of hyperkalemia is associated with reduction or cessation of RAAS inhibitors, which are both cardio- and renoprotective, while the new potassium binding agent can both allow the maintenance of the optimal RAASi dose but also might allow for less dietary restrictions and therefore an improvement in the nutrition status, giving an advantage especially to patients on hemodialysis. Given the scarce clinical studies performed on Sodium Zirconium Cyclosilicate in dialysis patients, as well as the need to provide more information about its efficacy and safety profile, there is a call for our clinical study. In this study we focused on the efficacy and safety profile of Sodium Zirconium Cyclosilicate after 2 weeks and 1 month from the initiation of the therapy both in non – dialysed and dialysed patients.
Sodium Zirconium Cyclosilicate: A new option for hyperkalemia treatment in Chronic Kidney Disease. A retrospective analysis
LISOWSKA, MARIA IRENA
2021/2022
Abstract
The plasma potassium level is normally maintained within narrow limits and kidney is primarily in charge of maintaining total body potassium content. Patients with CKD are more prone to develop imbalances of potassium homeostasis, such as hyperkalemia, which is defined as a serum or plasma potassium level usually greater than 5.0 mEq/L to 5.5 mEq/L. Hyperkalemia is not common in the general population, affecting less than 5% of the worldwide population, however its prevalence in hospitalized patients is reaching up to 10%. The need for hyperkalemia treatment comes from the very severe consequences of the potassium concentration imbalances, such as cardiac dysrhythmia, peripheral neuropathy and an increased risk of all-cause mortality and hospitalization. The new potassium binder called Sodium Zirconium Cyclosilicate is a revolutionary step for the treatment and prevention of hyperkalemia in high-risk patients, such as those in therapy with RAASi. In healthy people, the colon normally accounts for a small portion, about 5% to 10%, of total K+ excretion, while in patients with kidney disease, colon affects 50% of potassium excretion, thus making it a potential target for therapeutic treatment of increased concentration of potassium. This is a big advancement since the development of hyperkalemia is associated with reduction or cessation of RAAS inhibitors, which are both cardio- and renoprotective, while the new potassium binding agent can both allow the maintenance of the optimal RAASi dose but also might allow for less dietary restrictions and therefore an improvement in the nutrition status, giving an advantage especially to patients on hemodialysis. Given the scarce clinical studies performed on Sodium Zirconium Cyclosilicate in dialysis patients, as well as the need to provide more information about its efficacy and safety profile, there is a call for our clinical study. In this study we focused on the efficacy and safety profile of Sodium Zirconium Cyclosilicate after 2 weeks and 1 month from the initiation of the therapy both in non – dialysed and dialysed patients.È consentito all'utente scaricare e condividere i documenti disponibili a testo pieno in UNITESI UNIPV nel rispetto della licenza Creative Commons del tipo CC BY NC ND.
Per maggiori informazioni e per verifiche sull'eventuale disponibilità del file scrivere a: unitesi@unipv.it.
https://hdl.handle.net/20.500.14239/13664